Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Metis TechBio CoFRA:RO9 +7.99%17 EV-to-OCF is -149.11 as of Aug. 11, 2026. GuruFocus rates FRA:RO9 with a GF Score™ of 17/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Metis TechBio Co ranks better than 97.3% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Metis TechBio Co's Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-9.64 Mil. Therefore, Metis TechBio Co's EV-to-OCF for today is -149.11.
The historical rank and industry rank for Metis TechBio Co's EV-to-OCF or its related term are showing as below:
FRA:RO9'
s EV-to-OCF Range Over the Past 10 Years
Min: -304.75 Med: -178.72 Max: -133.77
Current: -166.09
During the past 4 years, the highest EV-to-OCF of Metis TechBio Co was -133.77. The lowest was -304.75. And the median was -178.72.
FRA:RO9's EV-to-OCF is ranked better than 97.3% of 1406
companies
in the Biotechnology industry
Industry Median: -3.515
vs FRA:RO9: -166.09
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Metis TechBio Co's PE Ratio (TTM) for today is calculated as:
Metis TechBio Co's share price for today is €1.284.
Metis TechBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Metis TechBio Co EV-to-OCF Related Terms
Metis TechBio Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Metis TechBio Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co EV-to-OCF Chart
Metis TechBio Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
EV-to-OCF
0.00
0.00
0.00
0.00
Metis TechBio Co Quarterly Data
Dec22
Dec23
Dec24
Sep25
Dec25
EV-to-OCF
0.00
0.00
0.00
0.00
0.00
FRA:RO9 vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, Metis TechBio Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metis TechBio Co EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metis TechBio Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Metis TechBio Co's EV-to-OCF falls into.
Metis TechBio Co's current Enterprise Value is €1,437.29 Mil.
Metis TechBio Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metis TechBio Co (FRA:RO9) has a EV-to-OCF of -149.11 as of Aug. 11, 2026. According to the industry distribution chart, Metis TechBio Co ranks #38 out of 1406 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Metis TechBio Co's EV-to-OCF too high?
Metis TechBio Co's current EV-to-OCF is -149.11. Based on the distribution chart, Metis TechBio Co ranks #38 out of 1406 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metis TechBio Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Metis TechBio Co's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Metis TechBio Co ranks #38 out of 1406 companies for EV-to-OCF. This places Metis TechBio Co in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Metis TechBio Co's current EV-to-OCF is -149.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metis TechBio Co stock overvalued right now?
Metis TechBio Co (FRA:RO9) has a current EV-to-OCF of -149.11. The current EV-to-OCF is -149.11. Metis TechBio Co's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Metis TechBio Co (FRA:RO9), the current EV-to-OCF is -149.11 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metis TechBio Co Ltd is an investment holding company. The company and its subsidiaries are principally engaged in AI-empowered nanomaterial innovation for the delivery and application of active agents across all carbon-based life forms. Its technology platform, NanoForge, comprises a set of integrated tools, including a lipid library, AI models, an AI agent (METiS), quantum chemistry and molecular dynamics simulations, and high-throughput screening platforms. The company has developed three solution platforms (AiTEM, AiLNP, and AiRNA) designed to simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of nanomaterials and their associated payloads.
17GF Score
Get the complete analysis for FRA:RO9
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RO9 has been successfully added to your 
